Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Taejoon Pharmaceutical Co. Ltd. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is handled by 1 distinct examiner in 1 distinct art unit, reflecting a singular focus for the company's active patent applications. This concentration suggests that the company is currently advancing its development through the Biotechnology & Pharmaceuticals examination process.
The busiest examiner, ATKINSON, JOSHUA ALEXANDER, manages 1 busiest examiner pending action. This represents the entirety of the company's 1 pending office action, meaning the current prosecution outcomes are tied to the specific docket of this 1 distinct examiner. For the practitioner, navigating the matter requires a deep understanding of the specific examination history and preferences of this individual. The presence of only 1 distinct art unit indicates that the company's current efforts are highly targeted rather than broadly distributed across different examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270476 | ORAL SOLID FORMULATION FOR COLON CLEANSING | ATKINSON, JOSHUA ALEXANDER | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270476 | ORAL SOLID FORMULATION FOR COLON CLEANSING | ATKINSON, JOSHUA ALEXANDER | 1612 | §102§103DP | Non-Final OA | 8d overdue | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial